Clinical outcomes of ruxolitinib treatment in 595 intermediate‐1 risk patients with myelofibrosis: The RUX‐MF Real‐World Study.

MLA

Palandri, Francesca, et al. “Clinical Outcomes of Ruxolitinib Treatment in 595 Intermediate‐1 Risk Patients with Myelofibrosis: The RUX‐MF Real‐World Study.” Cancer (0008543X), vol. 130, no. 24, Dec. 2024, pp. 4257–66. EBSCOhost, https://doi.org/10.1002/cncr.35489.

APA

Palandri, F., Elli, E. M., Morsia, E., Benevolo, G., Tiribelli, M., Beggiato, E., Bonifacio, M., Farina, M., Martino, B., Caocci, G., Pugliese, N., Tieghi, A., Crugnola, M., Binotto, G., Cavazzini, F., Abruzzese, E., Iurlo, A., Isidori, A., Bosi, C., & Guglielmana, V. (2024). Clinical outcomes of ruxolitinib treatment in 595 intermediate‐1 risk patients with myelofibrosis: The RUX‐MF Real‐World Study. Cancer (0008543X), 130(24), 4257–4266. https://doi.org/10.1002/cncr.35489

Chicago

Palandri, Francesca, Elena M. Elli, Erika Morsia, Giulia Benevolo, Mario Tiribelli, Eloise Beggiato, Massimiliano Bonifacio, et al. 2024. “Clinical Outcomes of Ruxolitinib Treatment in 595 Intermediate‐1 Risk Patients with Myelofibrosis: The RUX‐MF Real‐World Study.” Cancer (0008543X) 130 (24): 4257–66. doi:10.1002/cncr.35489.